Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company is headquartered in Bridgewater, New Jersey.
| Revenue (TTM) | $3.05B |
| Gross Profit (TTM) | $1.19B |
| EBITDA | $667.78M |
| Operating Margin | 19.60% |
| Return on Equity | -881.00% |
| Return on Assets | 8.35% |
| Revenue/Share (TTM) | $9.68 |
| Book Value | $-0.14 |
| Price-to-Book | 105.45 |
| Price-to-Sales (TTM) | 1.30 |
| EV/Revenue | 2.121 |
| EV/EBITDA | 10.32 |
| Quarterly Earnings Growth (YoY) | 384.60% |
| Quarterly Revenue Growth (YoY) | 3.90% |
| Shares Outstanding | $319.02M |
| Float | $178.41M |
| % Insiders | 44.12% |
| % Institutions | 52.10% |
Volatility is currently contracting